Hypertension

>

Latest News

AstraZeneca's Aldosterone Inhibitor Baxdrostat Effective Against Resistant HTN in Late-Stage Trial
AstraZeneca's Aldosterone Inhibitor Baxdrostat Effective Against Resistant HTN in Late-Stage Trial

July 14th 2025

Baxdrostat met the primary and all secondary endpoints, setting up a first regulatory filing for the selective aldosterone synthase inhibitor, according to AstraZeneca.

Coexisting HTN, T2D in US Adults Doubled Over 2 Decades: Daily Dose / image credit: ©New Africa/AdobeStock
Coexisting HTN, T2D in US Adults Doubled Over 2 Decades: Daily Dose

June 18th 2025

DASH4D Diet Reduces BP by 4.6 mm Hg in Adults with T2D on Maximal Antihypertensive Therapy
DASH4D Diet Reduces BP by 4.6 mm Hg in Adults with T2D on Maximal Antihypertensive Therapy

June 17th 2025

George Medicines Announces FDA Approval of Polypill for Treatment of Hypertension in Adults
George Medicines Announces FDA Approval of Polypill for Treatment of Hypertension in Adults

June 10th 2025

Coexisting Hypertension and Type 2 Diabetes in US Adults Doubled Over 2 Decades: New Study
Coexisting Hypertension and Type 2 Diabetes in US Adults Doubled Over 2 Decades: New Study

May 30th 2025

Video Interviews
Podcasts

More News

© 2025 MJH Life Sciences

All rights reserved.